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HIV/Aids –
a twenty-five-year rollercoaster
Hazel Barrett
n the spring of 2009 media headlines
appeared around the world that doctors
in Berlin believed they had found a cure
for HIV-AIDS. Bone marrow stem
cells had been used to treat leukaemia
in an HIV-positive male patient. Three
years after the treatment the patient
had no detectable signs of HIV, leading
to the claim that perhaps marrow
stem cells were the silver bullet the
world had been waiting for in the fight
against AIDS.
This highly optimistic story is just
one of many that have been reported
over the 25-year history of the global
HIV-AIDS pandemic that have raised
hopes that a cure or vaccine for HIV-
AIDS is close. Too often these hopes
are dashed. The search for a cure or
vaccine for HIV has been a 25-year
roller coaster of optimism followed by
despair.
The HIV virus was identified in
1983 by the French scientists
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Francoise Barre-Sinoussi and Luc Montagnier, work for which they were
awarded the Nobel Prize for Medicine in 2008. We are now entering the
third decade of the global HIV-AIDS pandemic and a cure or vaccine is as
distant as ever. Since the virus was identified the disease has spread to
every corner of the globe. In 2008, UNAIDS reported that 33 million people
globally were living with the disease, with 2.7 million people newly infected
in that year and 2 million dying. Since the beginning of the pandemic it is
estimated that 30 million people have died as a result of the infection.
These shocking data make this pandemic the most serious that humankind
has faced in its history.
AIDS is caused by HIV, which is a lentivirus, a member of the subgroup
of the retrovirus family. One of the main characteristics of the lentivirus is
its extensive genetic variability. Two types of HIV have been identified,
HIV-1 and HIV-2. HIV-1 is more transmissible and more pathogenic than
HIV-2. Each of these HIV types contains virologically related groups
comprising subtypes. Scientists have to date identified five groups and 20
subtypes of HIV, with the expectation that more will develop. However,
one subtype, HIV-1 Group M Subtype C, is responsible for 55–60% of all
global infections.
The HIV virus is highly unstable and susceptible to recombining. There
are thus many circulating recombinant forms of the virus which have
been formed using the genetic structures from two or more HIV subtypes.
This occurs when individuals are exposed to different groups and subtypes
of the virus. Within HIV-1 Group M, for example, there are at least 15
recombinant circulating forms. Co-infection with divergent HIV-1 strains
is relatively frequent, with over 20% of HIV infections in South-east Asia
attributed to recombinant circulating forms of HIV. At present no
recombinants have been reported between HIV-1 and HIV-2; however, as
the number of recombinant viruses increases the chance that they may
contribute to a new HIV group is high. In August 2009, scientists announced
the discovery of a new type of HIV in a woman from Cameroon, highlighting
the need to monitor for the emergence of new types of HIV.
The genetic variability of HIV is a major factor explaining why finding
a cure or vaccine for it has been so elusive. Despite unprecedented efforts
on vaccine research, it has proven difficult for scientists to produce a
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vaccine to counter so many subtypes of the virus. In addition, any vaccine
would have to be unable to recombine with existing HIV viruses to ensure
the vaccine did not accidentally produce new infecting HIV strains.
The nature of HIV infection and the long latency period of the infection
is another obstacle to finding a cure or vaccine for the disease. It can be
months after initial infection before the human body produces antibodies.
This is too late to fight the HIV infection, as by this time the virus has
stored itself in ‘reservoirs’, or anatomical sanctuaries in the body, such as
the lymph nodes of the intestines. These ‘stored’ viruses are not destroyed
by the body’s immune response, even after many years of antiretroviral
(ARV) treatment. This is shown in the reactivation of the virus if ARV
treatment is interrupted. If a cure or vaccine is to be effective, access to
these ‘resting cells’ during the latent period of the disease is vital.
As a result of these challenges, there have been many disappointments
concerning vaccine development. Following the collapse of a major clinical
trial of an AIDS vaccine (V520) by Merck at the end of 2007 (which may
have actually increased the chances of people developing AIDS), scientists
have become very pessimistic about the possibilities of successfully
developing an AIDS vaccine in the short to medium term using current
approaches.
In a survey of 35 leading UK and US scientists involved in AIDS
research undertaken by The Independent newspaper in April 2008, many
admitted that effective immunisation against HIV may not be possible.
There is a mood of deep pessimism amongst scientists researching AIDS
and there is currently much debate on the ethics of spending billions of
pounds on researching an AIDS vaccine rather than focussing on prevention
and treatment, at a time of increasing transmissible HIV resistance to ARVs.
Science has taught us much about the epidemiology of the HIV-AIDS
pandemic. We know the disease is transmitted from person to person in
infected bodily fluids, such as by using contaminated needles or having
unsafe sexual intercourse with an infected person. HIV-AIDS can thus be
classified as a ‘lifestyle’ disease, linked particularly to intimate sexual
behaviour, which is the leading route of transmission of the virus. This
means we need to pay greater attention to the economic and social factors
changing behaviour
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that drive risky behaviour and try to understand how these can be effectively
altered in a socially acceptable way. As with any lifestyle medical condition,
education combined with changing social expectations and norms can lead
to behavioural change that reduces the ‘risk’ environment in which people
live, and could ultimately control the spread of HIV.
Behavioural change, especially concerning sexual activity, is not easy
to achieve, as the HIV-AIDS pandemic has demonstrated, but it is possible.
Some countries in sub-Saharan Africa, the region most severely affected
by the pandemic, are reporting stabilisation or declines in HIV prevalence.
There is strong evidence that this is attributable to effective changes in
sexual behaviour, such as the postponement of sexual debut, reduction in
casual sexual relationships and more consistent use of condoms. Effective
public health campaigns such as the ABC Approach (where A translates
into sexual Abstinence, B is for Be faithful and C stands for use a Condom,
for the next letter in the alphabet is D which stands for Death), have been
largely responsible for a reduction in risky sexual behaviour in this region.
Education and behavioural change are not easy options. Humans are
constantly looking to science and technology to provide solutions so that
they do not have to change their behaviour. However, we could stop the
spread of HIV-AIDS in its tracks tomorrow before a cure or vaccine is
ready and at a fraction of the cost if we changed our behaviour. We just
need the will to do so.
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